ID   DU4475
AC   CVCL_1183
SY   Du4475; DU-4475; Du-4475; DU 4475; Du 4475; Duke University 4475
DR   CLO; CLO_0002842
DR   EFO; EFO_0002168
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7921
DR   ATCC; HTB-123
DR   BioGRID_ORCS_Cell_line; 684
DR   BioSample; SAMN03471772
DR   BioSample; SAMN03473595
DR   BioSample; SAMN05292453
DR   BioSample; SAMN10987660
DR   cancercelllines; CVCL_1183
DR   CCRID; 1101HUM-PUMC000342
DR   Cell_Model_Passport; SIDM01001
DR   ChEMBL-Cells; CHEMBL3308261
DR   ChEMBL-Targets; CHEMBL2366246
DR   CLS; 300371
DR   Cosmic; 685863
DR   Cosmic; 871141
DR   Cosmic; 904355
DR   Cosmic; 906844
DR   Cosmic; 921975
DR   Cosmic; 934523
DR   Cosmic; 997915
DR   Cosmic; 1046952
DR   Cosmic; 1047716
DR   Cosmic; 1091340
DR   Cosmic; 1152520
DR   Cosmic; 1287936
DR   Cosmic; 1289387
DR   Cosmic; 1609476
DR   Cosmic; 2164988
DR   Cosmic-CLP; 906844
DR   DepMap; ACH-000258
DR   DSMZ; ACC-427
DR   DSMZCellDive; ACC-427
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 906844
DR   GEO; GSM217568
DR   GEO; GSM274659
DR   GEO; GSM344345
DR   GEO; GSM344395
DR   GEO; GSM421865
DR   GEO; GSM783961
DR   GEO; GSM886989
DR   GEO; GSM888058
DR   GEO; GSM1053707
DR   GEO; GSM1669746
DR   IARC_TP53; 21043
DR   IGRhCellID; DU4475
DR   LiGeA; CCLE_395
DR   LINCS_HMS; 50577
DR   LINCS_LDP; LCL-1323
DR   PharmacoDB; DU4475_310_2019
DR   PRIDE; PXD008222
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1183
DR   PubChem_Cell_line; CVCL_1183
DR   SLKBase; 3415
DR   Wikidata; Q54831578
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=221108;
RX   PubMed=10862037;
RX   PubMed=11343771;
RX   PubMed=11414198;
RX   PubMed=12068308;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=18397470;
RX   PubMed=19593635;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23601657;
RX   PubMed=24094812;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25892236;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   Info; LINCS; ICBP43; https://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
WW   Info; Pawefish; -; https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/DU4475.html
WW   Info; Synapse; JWGray panel; https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   Info; Synapse; PS-ON; https://www.synapse.org/#!Synapse:syn31544500
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 2.9 days (PubMed=221108); 90 hours (PubMed=25984343); ~80-100 hours (DSMZ=ACC-427); ~32 hours (PBCF).
CC   HLA typing: A*03:01,31:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:6844; MAP2K4; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9884; RB1; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Glu1577Ter (c.4729G>T); Zygosity=Homozygous (PubMed=19593635; ATCC=HTB-123).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=18397470; PubMed=19593635; ATCC=HTB-123; Cosmic-CLP=906844; DepMap=ACH-000258).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.87%; Native American=0%; East Asian, North=3.81%; East Asian, South=0%; South Asian=0%; European, North=61.27%; European, South=34.04% (PubMed=30894373).
CC   Caution: Reported by some sites and publications to originate from a 62 year old woman, but the cell line was established when she was 70 year old.
CC   Misspelling: DU-475; Note=In text of PubMed 12702766.
CC   Misspelling: DU447; Cosmic=1609476.
CC   Discontinued: ATCC; CRL-7921; true.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC=HTB-123; CCRID=1101HUM-PUMC000342; CLS=300371; Cosmic-CLP=906844; DSMZ=ACC-427; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D12S391: 18.3,25
ST   D13S317: 11,14
ST   D16S539: 11,12
ST   D18S51: 14,16
ST   D19S433: 14
ST   D21S11: 29,31.2
ST   D2S1338: 20,25
ST   D3S1358: 14,16
ST   D5S818: 6,11 (DSMZ=ACC-427)
ST   D5S818: 11 (ATCC=HTB-123; CCRID=1101HUM-PUMC000342; CLS=300371; Cosmic-CLP=906844; PubMed=25877200)
ST   D6S1043: 11
ST   D7S820: 9,10
ST   D8S1179: 10,13
ST   FGA: 22,25
ST   Penta D: 13,14
ST   Penta E: 7,13
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 48
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
//
RX   PubMed=221108;
RA   Langlois A.J., Holder W.D. Jr., Iglehart J.D., Nelson-Rees W.A.,
RA   Wells S.A. Jr., Bolognesi D.P.;
RT   "Morphological and biochemical properties of a new human breast cancer
RT   cell line.";
RL   Cancer Res. 39:2604-2613(1979).
//
RX   PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B;
RA   Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F.,
RA   Isola J.J., Larsson C.;
RT   "Chromosomal alterations in 15 breast cancer cell lines by comparative
RT   genomic hybridization and spectral karyotyping.";
RL   Genes Chromosomes Cancer 28:308-317(2000).
//
RX   PubMed=11343771; DOI=10.1016/S0165-4608(00)00387-3;
RA   Rummukainen J., Kytola S., Karhu R., Farnebo F., Larsson C.,
RA   Isola J.J.;
RT   "Aberrations of chromosome 8 in 16 breast cancer cell lines by
RT   comparative genomic hybridization, fluorescence in situ
RT   hybridization, and spectral karyotyping.";
RL   Cancer Genet. Cytogenet. 126:1-7(2001).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=18397470; DOI=10.1111/j.1749-0774.2008.00046.x;
RA   Ueda M., Toji E., Nunobiki O., Izuma S., Okamoto Y., Torii K.,
RA   Noda S.;
RT   "Mutational analysis of the BRAF gene in human tumor cells.";
RL   Hum. Cell 21:13-17(2008).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A.F.A.S., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736;
RA   Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M.,
RA   Irie H.Y., Lee S.-I., Blau C.A., Villen J.;
RT   "The proteomic landscape of triple-negative breast cancer.";
RL   Cell Rep. 11:630-644(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035.1-140035.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//